SCHEMBL479458

SCHEMBL479458

CCOC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.47
GAA P10253 3/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
EPHX2 P34913 1/20 0.45
TRPV1 Q8NER1 1/20 0.45
CYP19A1 P11511 1/20 0.45
ALDH1A1 P00352 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MAPT P10636 5/20 0.43
NAMPT P43490 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
LMNA P02545 1/20 0.42
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479457 1.00 RXFP1 (0.49) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL479455 1.00 RXFP1 (0.49) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL4485304 0.94 SMN1; SMN2 (0.50) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL4485301 0.94 SMN1; SMN2 (0.50) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL481167 0.93 RXFP1 (0.51) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL481166 0.93 RXFP1 (0.51) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL2572324 0.92 RXFP1 (0.51) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL3159875 0.92 RXFP1 (0.51) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL2572320 0.92 RXFP1 (0.51) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL2569219 0.92 RXFP1 (0.51) RXFP1SMN1; SMN2GAARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3643309-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES Boehringer Ingelheim International GmbH (DE) 2020-04-29 EP disclosed
US-9844572-B2 Promotion of neuronal integration in neural stem cell grafts LIFE & BRAIN GMBH (DE) 2017-12-19 US disclosed
EP-2411034-B1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2017-07-26 EP disclosed
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2012-04-19 US disclosed
EP-2411034-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS Life & Brain GmbH (DE) 2012-02-01 EP disclosed
EP-2384751-A1 Medicaments for the treatment or prevention of fibrotic diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-09 EP disclosed
WO-2010108665-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS DCX, NGF, BDNF RXFP1 2731/4885SMN1; SMN2 60/4885GAA 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.